#462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy

Quality ID

462

eMeasure ID

CMS645v1

High Priority Measure

No

Specifications

EHR

Measure Type

Process

Specialty

General Oncology Urology

Measure description

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT

Register with MDinteractive